What is the prevalence of Uveitis?

Uveitis is considered a group of inflammatory eye conditions rather than a single disease, with an estimated global prevalence of approximately 50 to 115 cases per 100,000 people. While not classified as a rare disease in the general population, specific subtypes of uveitis are rare or ultra-rare, and prevalence varies significantly based on geographic location and underlying systemic associations.

What is the estimated prevalence and incidence of Uveitis?

Determining precise figures for uveitis is challenging because it is often secondary to other systemic conditions. Current clinical literature, including data from the NIH and international epidemiological studies, suggests an incidence rate of approximately 17 to 52 new cases per 100,000 person-years. Because uveitis can be chronic or recurrent, prevalence counts are often higher than incidence rates. It is important to note that these figures are estimates; many mild or asymptomatic cases remain undiagnosed, meaning the true burden of uveitis may be higher than recorded in traditional medical databases.

How do age, gender, and geography affect Uveitis?

The distribution of uveitis is influenced by several demographic factors:

• Age: While uveitis can occur at any age, it is most frequently diagnosed in adults between the ages of 20 and 50, which are the most productive years of life. Pediatric uveitis represents a smaller but clinically significant subset, often associated with juvenile idiopathic arthritis.


• Gender: Most studies indicate a slight female predominance in the prevalence of uveitis, though this can vary depending on the specific anatomical location of the inflammation (anterior vs. posterior).


• Geography and Ethnicity: There is a distinct geographic variation. For instance, Behçet’s disease-associated uveitis is more common in populations along the "Silk Road" (Middle East and East Asia), whereas HLA-B27 associated uveitis is more prevalent in Western populations.

Why is accurate data for Uveitis difficult to obtain?

The primary challenge in mapping the exact prevalence of uveitis lies in its classification. Uveitis is an umbrella term for inflammation of the uvea, encompassing over 30 distinct clinical entities. Many patients are treated in primary care or optometry settings for mild symptoms and are never formally coded for uveitis in hospital-based registries. Furthermore, because uveitis is frequently a manifestation of autoimmune diseases like sarcoidosis or multiple sclerosis, the eye condition is sometimes overshadowed by the primary diagnosis in health records.

What does the patient community tell us?

While clinical statistics provide a broad overview, patient-reported data offers a more nuanced look at the reality of living with this condition. Currently, 135 people with uveitis have joined the DiseaseMaps.org community to share their experiences. This real-world data is invaluable, as it highlights the diagnostic delays and the significant impact on quality of life that often go uncaptured in traditional epidemiological reports.

Next steps

• Consult an ophthalmologist specializing in uveitis (a uveitis specialist or ocular immunologist) for a comprehensive dilated eye exam.


• Keep a detailed symptom diary, noting frequency, intensity, and any associated systemic symptoms like joint pain or skin rashes.


• Connect with the DiseaseMaps.org community to share your journey and learn from others navigating the complexities of uveitis.


• Inquire with your physician about systemic testing to determine if your uveitis is idiopathic or secondary to an underlying autoimmune condition.

Medical disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician or other qualified health provider with any questions regarding a medical condition.

References

• National Institutes of Health (NIH) - Genetic and Rare Diseases Information Center (GARD).


• Orphanet: The portal for rare diseases and orphan drugs.


• American Uveitis Society (AUS) clinical guidelines and epidemiological summaries.


• PubMed/MEDLINE: Systematic reviews on the global epidemiology of non-infectious uveitis.